SG10201913262RA - Factor xi antibodies and methods of use - Google Patents

Factor xi antibodies and methods of use

Info

Publication number: SG10201913262RA
Authority: SG; Singapore
Prior art keywords: antibodies; factor; methods
Prior art date: 2015-06-26

Application number

SG10201913262RA

Inventor

Jorg Eder

Stefan Ewert

Ulrich Hassiepen

Yasser Khder

Lorenz M Mayr

Samu Melkko

Nikolaus Schiering

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-06-26

Filing date

2016-06-24

Publication date

2020-03-30

2016-06-24 Application filed by Novartis Ag filed Critical Novartis Ag

2020-03-30 Publication of SG10201913262RA publication Critical patent/SG10201913262RA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Microbiology (AREA)
Endocrinology (AREA)
Mycology (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Physics & Mathematics (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Plant Pathology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

SG10201913262RA 2015-06-26 2016-06-24 Factor xi antibodies and methods of use SG10201913262RA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201562184955P	2015-06-26	2015-06-26
US201662341568P	2016-05-25	2016-05-25

Publications (1)

Publication Number	Publication Date
SG10201913262RA true SG10201913262RA (en)	2020-03-30

Family

ID=56296875

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG10201913262RA SG10201913262RA (en)	2015-06-26	2016-06-24	Factor xi antibodies and methods of use

Country Status (28)

Country	Link
US (4)	US10465011B2 (en)
EP (1)	EP3313891A1 (en)
JP (4)	JP6698711B2 (en)
KR (2)	KR20190142448A (en)
CN (3)	CN107922505B (en)
AU (4)	AU2016281957B2 (en)
CA (1)	CA2990764A1 (en)
CL (1)	CL2017003261A1 (en)
CO (1)	CO2017013356A2 (en)
CR (1)	CR20170600A (en)
CU (1)	CU24498B1 (en)
EA (1)	EA036395B1 (en)
EC (1)	ECSP18005520A (en)
HK (1)	HK1250990A1 (en)
IL (3)	IL295859B2 (en)
JO (2)	JOP20200312A1 (en)
MA (1)	MA42243A (en)
MX (2)	MX391310B (en)
MY (2)	MY185813A (en)
PE (1)	PE20180480A1 (en)
PH (2)	PH12021551700A1 (en)
RU (1)	RU2739946C2 (en)
SG (1)	SG10201913262RA (en)
TN (1)	TN2017000536A1 (en)
TW (2)	TWI743039B (en)
UY (1)	UY36751A (en)
WO (1)	WO2016207858A1 (en)
ZA (1)	ZA201708589B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUE041556T2 (en) *	2008-06-19	2019-05-28	Prothix Bv	Use of anti-factor xi antibodies for prevention or treatment of thrombus formation
JOP20200312A1 (en) *	2015-06-26	2017-06-16	Novartis Ag	Factor xi antibodies and methods of use
EP3325010B1 (en) *	2015-07-23	2023-06-21	The Regents of The University of California	Antibodies to coagulation factor xia and uses thereof
AR107505A1 (en)	2016-01-22	2018-05-09	Merck Sharp & Dohme	ANTI-FACTOR COAGULATION ANTIBODIES XI
US11059905B2 (en)	2016-03-23	2021-07-13	Prothix B.V.	Monoclonal antibodies against the active site of factor XI and uses thereof
WO2017189964A2 (en)	2016-04-29	2017-11-02	Voyager Therapeutics, Inc.	Compositions for the treatment of disease
US11326182B2 (en)	2016-04-29	2022-05-10	Voyager Therapeutics, Inc.	Compositions for the treatment of disease
TW201802121A (en)	2016-05-25	2018-01-16	諾華公司	Reversal binding agent against factor XI/XIa antibody and use thereof
KR102218714B1 (en)	2016-06-14	2021-02-24	머크 샤프 앤드 돔 코포레이션	Anticoagulant factor XI antibody
DK3515947T3 (en)	2016-09-20	2024-07-29	Aronora Inc	Novel antibodies against factor XI and uses thereof
US20200231701A1 (en) *	2016-12-23	2020-07-23	Novartis Ag	Methods of treatment with anti-factor xi/xia antibodies
AU2017383232B2 (en) *	2016-12-23	2024-09-12	Novartis Ag	Factor XI antibodies and methods of use
CN108409863B (en) *	2017-02-10	2023-09-26	上海仁会生物制药股份有限公司	anti-factor XI antibodies
WO2020029179A1 (en) *	2018-08-09	2020-02-13	Shanghai Benemae Pharmaceutical Corporation	Anti-factor xi antibodies
US11958911B2 (en)	2017-02-10	2024-04-16	Shanghai Benemae Pharmaceutical	Anti-coagulation factor XI antibody
WO2019102353A1 (en)	2017-11-22	2019-05-31	Novartis Ag	Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
GB2569144B (en) *	2017-12-06	2021-06-16	Proimmune Ltd	Method for screening the activity of mutated expressed polypeptides
CN108220274B (en)	2017-12-11	2021-02-26	上海交通大学医学院附属瑞金医院	Preparation and application of high-activity coagulation factor XI mutant, gene therapy/editing vector and recombinant/fusion protein thereof
CN113474374B (en) *	2019-04-16	2025-05-02	四川科伦博泰生物医药股份有限公司	Anti-FXI/FXIa antibodies and uses thereof
CN110423278B (en)	2019-08-08	2020-07-17	上海博槿生物科技有限公司	Antibody against activated form factor XIa of coagulation factor XI and preparation method and application thereof
BR112022012064A2 (en) *	2019-12-20	2022-08-30	Anthos Therapeutics Inc	FORMULATION OF INTRAVENOUS DRUG DELIVERY, VIAL COMPRISING THE SAME AND METHOD OF TREATMENT OF A SUBJECT AFFECTED BY OR AT RISK OF DEVELOPING A THROMBOEMBOLIC DISORDER
GB2595299B (en)	2020-05-21	2022-08-03	Mabsolve Ltd	Modified immunoglobulin FC regions
TWI882142B (en) *	2020-07-02	2025-05-01	大陸商北京拓界生物醫藥科技有限公司	An anti-fxi/fxia antibody, the antigen-binding fragment and the medical use thereof
KR20230121120A (en) *	2020-12-18	2023-08-17	안토스 테라퓨틱스, 인크.	Methods for detecting anti-drug antibodies to factor XI and/or factor XIA antibodies
WO2024102369A1 (en)	2022-11-07	2024-05-16	Regeneron Pharmaceuticals, Inc.	Factor xi catalytic domain-binding antibodies and methods of use thereof
AU2024217729A1 (en)	2023-02-08	2025-08-21	Immunos Therapeutics Ag	FUSION PROTEINS OF ß2 MICROGLOBULIN, HLA HEAVY CHAIN POLYPEPTIDES, AND INHIBITOR OF CD47-SIRPA
WO2025149667A1 (en)	2024-01-12	2025-07-17	Pheon Therapeutics Ltd	Antibody drug conjugates and uses thereof

Family Cites Families (134)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5179017A (en)	1980-02-25	1993-01-12	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en)	1980-02-25	1987-01-06	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4458066A (en)	1980-02-29	1984-07-03	University Patents, Inc.	Process for preparing polynucleotides
US4447233A (en)	1981-04-10	1984-05-08	Parker-Hannifin Corporation	Medication infusion pump
US4439196A (en)	1982-03-18	1984-03-27	Merck & Co., Inc.	Osmotic drug delivery system
US4447224A (en)	1982-09-20	1984-05-08	Infusaid Corporation	Variable flow implantable infusion apparatus
US4487603A (en)	1982-11-26	1984-12-11	Cordis Corporation	Implantable microinfusion pump system
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4486194A (en)	1983-06-08	1984-12-04	James Ferrara	Therapeutic device for administering medicaments through the skin
EP0154316B1 (en)	1984-03-06	1989-09-13	Takeda Chemical Industries, Ltd.	Chemically modified lymphokine and production thereof
JPS6147500A (en)	1984-08-15	1986-03-07	Res Dev Corp Of Japan	Chimeric monoclonal antibody and its production method
EP0173494A3 (en)	1984-08-27	1987-11-25	The Board Of Trustees Of The Leland Stanford Junior University	Chimeric receptors by dna splicing and expression
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
JPS61134325A (en)	1984-12-04	1986-06-21	Teijin Ltd	Expression of hybrid antibody gene
US4596556A (en)	1985-03-25	1986-06-24	Bioject, Inc.	Hypodermic injection apparatus
JPH0656382B2 (en)	1985-09-17	1994-07-27	和光純薬工業株式会社	Immunological assay for active human blood coagulation factor XI
WO1987002671A1 (en)	1985-11-01	1987-05-07	International Genetic Engineering, Inc.	Modular assembly of antibody genes, antibodies prepared thereby and use
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US5260203A (en)	1986-09-02	1993-11-09	Enzon, Inc.	Single polypeptide chain binding molecules
US4881175A (en)	1986-09-02	1989-11-14	Genex Corporation	Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
AU600575B2 (en)	1987-03-18	1990-08-16	Sb2, Inc.	Altered antibodies
US5013653A (en)	1987-03-20	1991-05-07	Creative Biomolecules, Inc.	Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5258498A (en)	1987-05-21	1993-11-02	Creative Biomolecules, Inc.	Polypeptide linkers for production of biosynthetic proteins
US5132405A (en)	1987-05-21	1992-07-21	Creative Biomolecules, Inc.	Biosynthetic antibody binding sites
US5091513A (en)	1987-05-21	1992-02-25	Creative Biomolecules, Inc.	Biosynthetic antibody binding sites
DE3853515T3 (en)	1987-05-21	2005-08-25	Micromet Ag	MULTIFUNCTIONAL PROTEINS WITH SPECIFIC OBJECTIVES.
US4790824A (en)	1987-06-19	1988-12-13	Bioject, Inc.	Non-invasive hypodermic injection device
US4941880A (en)	1987-06-19	1990-07-17	Bioject, Inc.	Pre-filled ampule and non-invasive hypodermic injection device assembly
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
US5677425A (en)	1987-09-04	1997-10-14	Celltech Therapeutics Limited	Recombinant antibody
US5336603A (en)	1987-10-02	1994-08-09	Genentech, Inc.	CD4 adheson variants
GB8809129D0 (en)	1988-04-18	1988-05-18	Celltech Ltd	Recombinant dna methods vectors and host cells
US4963657A (en)	1988-06-09	1990-10-16	Temple University Of The Commonwealth System Of Higher Education	Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
KR900005995A (en)	1988-10-31	1990-05-07	우메모또 요시마사	Modified Interleukin-2 and Method of Making the Same
EP0401384B1 (en)	1988-12-22	1996-03-13	Kirin-Amgen, Inc.	Chemically modified granulocyte colony stimulating factor
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5112946A (en)	1989-07-06	1992-05-12	Repligen Corporation	Modified pf4 compositions and methods of use
FR2650598B1 (en)	1989-08-03	1994-06-03	Rhone Poulenc Sante	DERIVATIVES OF ALBUMIN WITH THERAPEUTIC FUNCTION
WO1991006570A1 (en)	1989-10-25	1991-05-16	The University Of Melbourne	HYBRID Fc RECEPTOR MOLECULES
US5312335A (en)	1989-11-09	1994-05-17	Bioject Inc.	Needleless hypodermic injection device
US5064413A (en)	1989-11-09	1991-11-12	Bioject, Inc.	Needleless hypodermic injection device
US5349053A (en)	1990-06-01	1994-09-20	Protein Design Labs, Inc.	Chimeric ligand/immunoglobulin molecules and their uses
KR100272077B1 (en)	1990-08-29	2000-11-15	젠팜인터내셔날,인코포레이티드	Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
AU643109B2 (en)	1990-12-14	1993-11-04	Cell Genesys, Inc.	Chimeric chains for receptor-associated signal transduction pathways
DE4118120A1 (en)	1991-06-03	1992-12-10	Behringwerke Ag	TETRAVALENT BISPECIFIC RECEPTORS, THEIR PRODUCTION AND USE
DE69233204T2 (en)	1991-12-13	2004-07-15	Xoma Corp., Berkeley	METHOD AND MATERIALS FOR THE PRODUCTION OF MODIFIED VARIABLE ANTIBODY DOMAINS AND THEIR THERAPEUTIC USE
US5622929A (en)	1992-01-23	1997-04-22	Bristol-Myers Squibb Company	Thioether conjugates
FR2686899B1 (en)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2686901A1 (en)	1992-01-31	1993-08-06	Rhone Poulenc Rorer Sa	NOVEL ANTITHROMBOTIC POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US5714350A (en)	1992-03-09	1998-02-03	Protein Design Labs, Inc.	Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5447851B1 (en)	1992-04-02	1999-07-06	Univ Texas System Board Of	Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
CA2118508A1 (en)	1992-04-24	1993-11-11	Elizabeth S. Ward	Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5383851A (en)	1992-07-24	1995-01-24	Bioject Inc.	Needleless hypodermic injection device
EP0656946B2 (en)	1992-08-21	2010-03-31	Vrije Universiteit Brussel	Immunoglobulins devoid of light chains
WO1994029351A2 (en)	1993-06-16	1994-12-22	Celltech Limited	Antibodies
AU1397895A (en)	1993-12-22	1995-07-10	Temple University - Of The Commonwealth System Of Higher Education	Peptide analogs of the activated platelet binding site on factor xi
SE9400088D0 (en)	1994-01-14	1994-01-14	Kabi Pharmacia Ab	Bacterial receptor structures
US5834252A (en)	1995-04-18	1998-11-10	Glaxo Group Limited	End-complementary polymerase reaction
US5605793A (en)	1994-02-17	1997-02-25	Affymax Technologies N.V.	Methods for in vitro recombination
US5837458A (en)	1994-02-17	1998-11-17	Maxygen, Inc.	Methods and compositions for cellular and metabolic engineering
FR2718312B1 (en)	1994-03-29	1996-06-07	Rola Nevoux	Method for the combined authentication of a telecommunications terminal and a user module.
AU3382595A (en)	1994-07-29	1996-03-04	Smithkline Beecham Corporation	Novel compounds
US5641870A (en)	1995-04-20	1997-06-24	Genentech, Inc.	Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en)	1995-04-14	1999-02-09	Genentech, Inc.	Altered polypeptides with increased half-life
US6121022A (en)	1995-04-14	2000-09-19	Genentech, Inc.	Altered polypeptides with increased half-life
MA24512A1 (en)	1996-01-17	1998-12-31	Univ Vermont And State Agrienl	PROCESS FOR THE PREPARATION OF ANTICOAGULATING AGENTS USEFUL IN THE TREATMENT OF THROMBOSIS
WO1997034631A1 (en)	1996-03-18	1997-09-25	Board Of Regents, The University Of Texas System	Immunoglobin-like domains with increased half lives
WO1998023289A1 (en)	1996-11-27	1998-06-04	The General Hospital Corporation	MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en)	1997-03-03	2001-08-21	Board Of Regents, The University Of Texas System	Immunoglobulin-like domains with increased half-lives
ES2258817T3 (en)	1997-05-21	2006-09-01	Biovation Limited	METHOD FOR THE PRODUCTION OF NON-IMMUNOGEN PROTEINS.
WO1998056906A1 (en)	1997-06-11	1998-12-17	Thoegersen Hans Christian	Trimerising module
EP0985039B1 (en)	1997-06-12	2008-02-20	Novartis International Pharmaceutical Ltd.	Artificial antibody polypeptides
DE19742706B4 (en)	1997-09-26	2013-07-25	Pieris Proteolab Ag	lipocalin muteins
US6194551B1 (en)	1998-04-02	2001-02-27	Genentech, Inc.	Polypeptide variants
JP4334141B2 (en)	1998-04-20	2009-09-30	グリカートバイオテクノロジーアクチェンゲゼルシャフト	Engineering glycosylation of antibodies to improve antibody-dependent cytotoxicity
US6818418B1 (en)	1998-12-10	2004-11-16	Compound Therapeutics, Inc.	Protein scaffolds for antibody mimics and other binding proteins
BR0008758A (en)	1999-01-15	2001-12-04	Genentech Inc	Variants of parental polypeptides with altered effector function, polypeptides, isolated nucleic acid composition, vector, host cell, method for producing a polypeptide variant, method for treating a disorder in mammals and method for producing a variant fc region
CA2369292C (en)	1999-04-09	2010-09-21	Kyowa Hakko Kogyo Co. Ltd.	Method of modulating the activity of functional immune molecules
DE19932688B4 (en)	1999-07-13	2009-10-08	Scil Proteins Gmbh	Design of beta-sheet proteins of gamma-II-crystalline antibody-like
EP1990409A3 (en)	1999-07-20	2011-05-18	MorphoSys AG	Bacteriophage
CA2405550A1 (en)	2000-04-12	2001-10-25	Human Genome Sciences, Inc.	Albumin fusion proteins
US7560534B2 (en)	2000-05-08	2009-07-14	Celldex Research Corporation	Molecular conjugates comprising human monoclonal antibodies to dendritic cells
WO2002057445A1 (en)	2000-05-26	2002-07-25	National Research Council Of Canada	Single-domain brain-targeting antibody fragments derived from llama antibodies
KR100890088B1 (en)	2001-02-12	2009-03-24	메다렉스, 인코포레이티드	Human Monoclonal Antibody Against Fc Alpha Receptor (CDV)
US20050053973A1 (en)	2001-04-26	2005-03-10	Avidia Research Institute	Novel proteins with targeted binding
US20050048512A1 (en)	2001-04-26	2005-03-03	Avidia Research Institute	Combinatorial libraries of monomer domains
US20040175756A1 (en)	2001-04-26	2004-09-09	Avidia Research Institute	Methods for using combinatorial libraries of monomer domains
JP2004532038A (en)	2001-05-17	2004-10-21	ディヴァーサコーポレイション	Application of novel antigen-binding molecules to therapeutic, diagnostic, prophylactic, enzymatic, industrial and agricultural fields, and methods for producing and screening novel antigen-binding molecules therefor
CZ200438A3 (en)	2001-06-13	2004-06-16	Genmab A/S	The title is not available
IL160358A0 (en)	2001-08-23	2004-07-25	Genmab As	Human antibodies specific for interleukin 15 (il-15)
ATE430580T1 (en)	2001-10-25	2009-05-15	Genentech Inc	GLYCOPROTEIN COMPOSITIONS
WO2003074679A2 (en)	2002-03-01	2003-09-12	Xencor	Antibody optimization
WO2004035607A2 (en)	2002-10-17	2004-04-29	Genmab A/S	Human monoclonal antibodies against cd20
WO2004043989A2 (en)	2002-11-07	2004-05-27	Medarex, Inc.	Human monoclonal antibodies to heparanase
US20040180855A1 (en)	2003-02-19	2004-09-16	Schumacher William A.	Methods of treating thrombosis with reduced risk of increased bleeding times
WO2004089297A2 (en)	2003-04-02	2004-10-21	Suntory Pharmaceutical Research Laboratories, Llc	Compounds and methods for treatment of thrombosis
DE10324447A1 (en)	2003-05-28	2004-12-30	Scil Proteins Gmbh	Generation of artificial binding proteins based on ubiquitin
CA2529001A1 (en)	2003-06-10	2004-12-16	Catchmabs B.V.	Binding peptides: methods for their generation and use
CN1832920A (en)	2003-08-08	2006-09-13	特兰斯泰克制药公司	Aryl and heteroaryl compounds, compositions, and methods of use
EP1761561B1 (en)	2004-01-20	2015-08-26	KaloBios Pharmaceuticals, Inc.	Antibody specificity transfer using minimal essential binding determinants
US20060008844A1 (en)	2004-06-17	2006-01-12	Avidia Research Institute	c-Met kinase binding proteins
US20080146811A1 (en)	2004-07-23	2008-06-19	Hongfeng Deng	Compounds and Methods For Treatment of Thrombosis
BRPI0518151A2 (en)	2004-10-13	2009-06-16	Ablynx Nv	polypeptides against amyloid-beta, nucleic acid encoding such polypeptide, composition comprising such polypeptide, method for producing a polypeptide and use thereof
US7459564B2 (en)	2005-01-13	2008-12-02	Bristol-Myers Squibb Company	Substituted biaryl compounds as factor XIa inhibitors
WO2006108039A2 (en)	2005-04-04	2006-10-12	Daiamed, Inc.	Substituted azetidinones
CA2633252A1 (en)	2005-12-14	2007-06-21	Bristol-Myers Squibb Company	Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
AU2008326348B2 (en) *	2007-11-21	2014-01-30	Oregon Health & Science University	Anti-factor XI monoclonal antibodies and methods of use thereof
JP5537442B2 (en)	2008-03-13	2014-07-02	ブリストル−マイヤーズスクイブカンパニー	Pyridazine derivatives as factor XIA inhibitors
FR2931481B1 (en)	2008-05-23	2013-05-10	Covalab	PROPIONYLE / BUTYRYLEE LYSINE-SPECIFIC ANTIBODY, METHOD FOR PRODUCING THE SAME, AND APPLICATIONS THEREOF
HUE041556T2 (en)	2008-06-19	2019-05-28	Prothix Bv	Use of anti-factor xi antibodies for prevention or treatment of thrombus formation
CN104212799B (en)	2008-10-15	2018-11-23	Ionis制药公司	The adjusting of factor 11 expression
AU2009335643B2 (en) *	2008-12-18	2014-05-29	Oregon Health & Science University	Anti-fXI antibodies and methods of use
SI2847228T1 (en) *	2012-05-10	2018-11-30	Bayer Pharma Aktiengesellschaft	Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
US8940833B2 (en)	2013-03-15	2015-01-27	Brady Worldwide, Inc.	Polyester-based, pressure sensitive adhesive
JOP20200312A1 (en)	2015-06-26	2017-06-16	Novartis Ag	Factor xi antibodies and methods of use
EP3325010B1 (en)	2015-07-23	2023-06-21	The Regents of The University of California	Antibodies to coagulation factor xia and uses thereof
CA2993885A1 (en)	2015-08-06	2017-02-09	Glycotope Gmbh	Heteromers comprising antibody domain fusion proteins
AR107505A1 (en)	2016-01-22	2018-05-09	Merck Sharp & Dohme	ANTI-FACTOR COAGULATION ANTIBODIES XI
US11059905B2 (en)	2016-03-23	2021-07-13	Prothix B.V.	Monoclonal antibodies against the active site of factor XI and uses thereof
TW201802121A (en)	2016-05-25	2018-01-16	諾華公司	Reversal binding agent against factor XI/XIa antibody and use thereof
KR102218714B1 (en)	2016-06-14	2021-02-24	머크 샤프 앤드 돔 코포레이션	Anticoagulant factor XI antibody
DK3515947T3 (en)	2016-09-20	2024-07-29	Aronora Inc	Novel antibodies against factor XI and uses thereof
US20190248920A1 (en)	2016-09-23	2019-08-15	Csl Limited	Coagulation factor binding proteins and uses thereof
AU2017383232B2 (en)	2016-12-23	2024-09-12	Novartis Ag	Factor XI antibodies and methods of use
US20200231701A1 (en)	2016-12-23	2020-07-23	Novartis Ag	Methods of treatment with anti-factor xi/xia antibodies
BR112019014785A2 (en)	2017-01-19	2020-05-12	Bayer Pharma Aktiengesellschaft	NEW STABLE FORMULATION FOR FXIA ANTIBODIES

2015
- 2015-06-26 JO JOP/2020/0312A patent/JOP20200312A1/en unknown
2016
- 2016-06-23 JO JOP/2016/0131A patent/JOP20160131B1/en active
- 2016-06-23 UY UY0001036751A patent/UY36751A/en active IP Right Grant
- 2016-06-24 TW TW105120045A patent/TWI743039B/en active
- 2016-06-24 MX MX2017017144A patent/MX391310B/en unknown
- 2016-06-24 CN CN201680048982.9A patent/CN107922505B/en active Active
- 2016-06-24 CN CN202210054073.3A patent/CN114380914A/en active Pending
- 2016-06-24 JP JP2017567115A patent/JP6698711B2/en active Active
- 2016-06-24 TW TW110134602A patent/TWI820482B/en active
- 2016-06-24 KR KR1020197037455A patent/KR20190142448A/en not_active Ceased
- 2016-06-24 RU RU2018102798A patent/RU2739946C2/en active
- 2016-06-24 KR KR1020187002094A patent/KR102059059B1/en active Active
- 2016-06-24 IL IL295859A patent/IL295859B2/en unknown
- 2016-06-24 PH PH1/2021/551700A patent/PH12021551700A1/en unknown
- 2016-06-24 IL IL318883A patent/IL318883A/en unknown
- 2016-06-24 PE PE2017002813A patent/PE20180480A1/en unknown
- 2016-06-24 CR CR20170600A patent/CR20170600A/en unknown
- 2016-06-24 MY MYPI2017704853A patent/MY185813A/en unknown
- 2016-06-24 MA MA042243A patent/MA42243A/en unknown
- 2016-06-24 EP EP16734042.1A patent/EP3313891A1/en active Pending
- 2016-06-24 AU AU2016281957A patent/AU2016281957B2/en active Active
- 2016-06-24 US US15/192,020 patent/US10465011B2/en active Active
- 2016-06-24 WO PCT/IB2016/053790 patent/WO2016207858A1/en not_active Ceased
- 2016-06-24 IL IL256376A patent/IL256376B/en unknown
- 2016-06-24 HK HK18110257.7A patent/HK1250990A1/en unknown
- 2016-06-24 CN CN202210442713.8A patent/CN114773479A/en active Pending
- 2016-06-24 EA EA201890145A patent/EA036395B1/en unknown
- 2016-06-24 CA CA2990764A patent/CA2990764A1/en active Pending
- 2016-06-24 CU CU2017000169A patent/CU24498B1/en unknown
- 2016-06-24 TN TNP/2017/000536A patent/TN2017000536A1/en unknown
- 2016-06-24 US US15/739,414 patent/US20180355056A1/en not_active Abandoned
- 2016-06-24 SG SG10201913262RA patent/SG10201913262RA/en unknown
- 2016-06-24 MY MYPI2020005425A patent/MY194928A/en unknown
2017
- 2017-12-18 ZA ZA2017/08589A patent/ZA201708589B/en unknown
- 2017-12-19 PH PH12017502358A patent/PH12017502358A1/en unknown
- 2017-12-19 CL CL2017003261A patent/CL2017003261A1/en unknown
- 2017-12-20 MX MX2022004072A patent/MX2022004072A/en unknown
- 2017-12-22 CO CONC2017/0013356A patent/CO2017013356A2/en unknown
2018
- 2018-01-25 EC ECIEPI20185520A patent/ECSP18005520A/en unknown
2019
- 2019-09-24 US US16/580,963 patent/US20200115468A1/en not_active Abandoned
- 2019-11-11 AU AU2019264514A patent/AU2019264514B2/en active Active
2020
- 2020-03-09 JP JP2020039843A patent/JP2020114216A/en not_active Withdrawn
2021
- 2021-11-25 AU AU2021273615A patent/AU2021273615B2/en active Active
2022
- 2022-05-13 JP JP2022079828A patent/JP7587550B2/en active Active
2023
- 2023-01-20 US US18/157,312 patent/US20240067750A1/en active Pending
- 2023-11-24 JP JP2023199171A patent/JP2024026169A/en active Pending
2025
- 2025-03-11 AU AU2025201731A patent/AU2025201731A1/en active Pending

Also Published As

Publication number	Publication date
PH12017502358A1 (en)	2018-06-25
BR112017027778A2 (en)	2018-10-09
RU2739946C2 (en)	2020-12-30
IL318883A (en)	2025-04-01
CU24498B1 (en)	2021-01-12
NZ777273A (en)	2025-05-30
IL295859B1 (en)	2025-03-01
CU20170169A7 (en)	2018-07-05
JOP20200312A1 (en)	2017-06-16
RU2018102798A (en)	2019-07-29
JP2024026169A (en)	2024-02-28
US20200115468A1 (en)	2020-04-16
US20240067750A1 (en)	2024-02-29
WO2016207858A1 (en)	2016-12-29
AU2025201731A1 (en)	2025-04-03
US20180355056A1 (en)	2018-12-13
RU2020142517A (en)	2021-01-27
MX2017017144A (en)	2018-05-28
JP7587550B2 (en)	2024-11-20
CN107922505A (en)	2018-04-17
AU2016281957B2 (en)	2019-08-15
PE20180480A1 (en)	2018-03-07
KR20180019733A (en)	2018-02-26
TW202222839A (en)	2022-06-16
ZA201708589B (en)	2018-11-28
HK1250990A1 (en)	2019-01-18
MY194928A (en)	2022-12-23
EP3313891A1 (en)	2018-05-02
NZ738480A (en)	2025-03-28
PH12021551700A1 (en)	2022-11-07
TWI743039B (en)	2021-10-21
MA42243A (en)	2018-05-02
IL295859A (en)	2022-10-01
CN114380914A (en)	2022-04-22
JP2018526976A (en)	2018-09-20
IL256376B (en)	2022-09-01
ECSP18005520A (en)	2018-04-30
AU2019264514A1 (en)	2019-12-05
US10465011B2 (en)	2019-11-05
JOP20160131B1 (en)	2022-03-14
MX391310B (en)	2025-03-21
AU2016281957A1 (en)	2018-01-18
TWI820482B (en)	2023-11-01
UY36751A (en)	2017-01-31
CR20170600A (en)	2018-02-28
CO2017013356A2 (en)	2018-03-20
RU2018102798A3 (en)	2020-05-22
KR102059059B1 (en)	2020-02-12
EA201890145A1 (en)	2018-07-31
CA2990764A1 (en)	2016-12-29
CN107922505B (en)	2022-05-06
AU2019264514B2 (en)	2021-12-09
JP2022116069A (en)	2022-08-09
MY185813A (en)	2021-06-10
CL2017003261A1 (en)	2018-04-20
IL295859B2 (en)	2025-07-01
MX2022004072A (en)	2022-05-03
AU2021273615B2 (en)	2024-12-12
CN114773479A (en)	2022-07-22
KR20190142448A (en)	2019-12-26
US20170022292A1 (en)	2017-01-26
JP2020114216A (en)	2020-07-30
AU2021273615A1 (en)	2021-12-16
TN2017000536A1 (en)	2019-04-12
TW201722993A (en)	2017-07-01
EA036395B1 (en)	2020-11-05
JP6698711B2 (en)	2020-05-27
IL256376A (en)	2018-02-28

Publication	Publication Date	Title
IL304117A (en)	2023-09-01	Anti-pvrig antibodies and methods of use
IL279606A (en)	2021-03-01	Anti-trem2 antibodies and methods of use thereof
ZA201708589B (en)	2018-11-28	Factor xi antibodies and methods of use
IL259495A (en)	2018-07-31	Antibodies and methods of use thereof
IL257636A (en)	2018-04-30	Anti-tigit antibodies and methods of use
IL254887A0 (en)	2017-12-31	Anti-sortilin antibodies and methods of use thereof
SG11201803567XA (en)	2018-05-30	Anti-siglec-9 antibodies and methods of use thereof
SG10201912150TA (en)	2020-02-27	Anti-trem2 antibodies and methods of use thereof
IL259681A (en)	2018-07-31	Novel anti-claudin antibodies and methods of use
ZA202001985B (en)	2022-12-21	Anti-htra1 antibodies and methods of use thereof
IL267538A (en)	2019-08-29	Factor xi antibodies and methods of use